p53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue

被引:32
作者
Broll, R [1 ]
Duchrow, M [1 ]
Oevermann, E [1 ]
Wellm, C [1 ]
Schwandner, O [1 ]
Schimmelpenning, H [1 ]
Roblick, UJ [1 ]
Bruch, HP [1 ]
Windhövel, U [1 ]
机构
[1] Univ Clin Lubeck, Surg Res Lab, D-23538 Lubeck, Germany
关键词
tumor suppressor gene p53; p53; autoantibodies; immunohistochemistry; p53 protein concentration; colorectal cancer;
D O I
10.1007/s003840000263
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We evaluated p53 autoantibodies (p53-Ab) as a preoperative tumor marker and as a prognosis marker. We also investigated whether p53-Ab production is dependent on p53 protein overexpression in tumor tissue or on tumor volume. Serum samples of patients with a colorectal cancer (n=130) and of healthy controls (n=44) were examined for p53-Ab using an ELISA kit. P53 protein expression in tumor tissue was demonstrated immunohistochemically and quantified by ELISA. Tumor volume was calculated and patients' survival computed using the Kaplan-Meier method. p53-Ab were detected in the serum from 15% of patients; all controls were negative. There was a significant correlation between p53-Ab production and positive immunostaining or p53 protein concentration in tumor tissue. p53-Ab were detected at a higher percentage of patients with a tumor volume of 10 cm(3) or greater than in those with a smaller tumor. No difference in patients' prognosis was found between the p53-Ab positive and negative groups. Because of their low sensitivity (15%) p53-Ab are not suitable as a preoperative tumor marker. However, their high specificity (100%) and their potential for early diagnosis of a tumor relapse makes them valuable for postoperative monitoring during follow-up in p53-Ab positive patients. Furthermore, their detection can be used as a simple serological test for early detection of p53 alterations.
引用
收藏
页码:22 / 27
页数:6
相关论文
共 26 条
[1]   PREVALENCE OF SERUM ANTIBODIES AGAINST THE P53 TUMOR-SUPPRESSOR GENE PROTEIN IN VARIOUS CANCERS [J].
ANGELOPOULOU, K ;
DIAMANDIS, EP ;
SUTHERLAND, DJA ;
KELLEN, JA ;
BUNTING, PS .
INTERNATIONAL JOURNAL OF CANCER, 1994, 58 (04) :480-487
[2]   Expression of p53 and mdm2 mRNA and protein in colorectal carcinomas [J].
Broll, R ;
Stark, A ;
Windhövel, U ;
Best, R ;
Strik, MW ;
Schimmelpenning, H ;
Schwandner, O ;
Kujath, P ;
Bruch, HP ;
Duchrow, M .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (07) :1083-1088
[3]   Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancer [J].
Coomber, D ;
Hawkins, NJ ;
Clark, M ;
Meagher, A ;
Ward, RL .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1996, 122 (12) :757-762
[4]   DETECTION OF ANTIBODIES AGAINST THE CELLULAR PROTEIN P53 IN SERA FROM PATIENTS WITH BREAST-CANCER [J].
CRAWFORD, LV ;
PIM, DC ;
BULBROOK, RD .
INTERNATIONAL JOURNAL OF CANCER, 1982, 30 (04) :403-408
[5]   IMMUNE-RESPONSE TO P53 IS DEPENDENT UPON P53/HSP70 COMPLEXES IN BREAST CANCERS [J].
DAVIDOFF, AM ;
IGLEHART, JD ;
MARKS, JR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (08) :3439-3442
[6]  
Hallak R, 1998, INT J ONCOL, V12, P785
[7]  
Hammel P, 1999, INT J CANCER, V81, P712, DOI 10.1002/(SICI)1097-0215(19990531)81:5<712::AID-IJC7>3.0.CO
[8]  
2-0
[9]   ANTIBODIES AGAINST P53 ARE ASSOCIATED WITH POOR-PROGNOSIS OF COLORECTAL-CANCER [J].
HOUBIERS, JGA ;
VANDERBURG, SH ;
VANDEWATERING, LMG ;
TOLLENAAR, RAEM ;
BRAND, A ;
VANDEVELDE, CJH ;
MELIEF, CJM .
BRITISH JOURNAL OF CANCER, 1995, 72 (03) :637-641
[10]  
LABRECQUE S, 1993, CANCER RES, V53, P3468